Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-533 · 1 trial · 1 indication
RP2D as determined by interval 3+3 dose escalation design
Safety and tolerability of ORIC-533
Safety and tolerability of ORIC-533
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ORIC-533 dosed orally, once per day of each consecutive 28-day cycle. |
| Dose Expansion | EXPERIMENTAL | RP2D dose |
| Name | Type | Description |
|---|---|---|
| ORIC-533 | DRUG | ORIC-533 once daily in consecutive 28-day cycles |
Inclusion Criteria: * Diagnosis of multiple myeloma (MM) with relapsed or refractory disease according to IMWG Criteria * Refractory to or not eligible for MM treatment regimens known to provide clinical benefit, including but not limited to an immunomodulatory agent, a proteasome inhibitor, and an...
Top 20 of 25 competitors
ORIC-533 is an investigational small molecule being studied for the treatment of relapsed or refractory multiple myeloma, a cancer of plasma cells in the bone marrow. It is being developed by Oric Pharmaceuticals, Inc. as an oral therapy for patients whose disease has returned or stopped responding to prior treatment.
ORIC-533 targets CD73, a protein involved in the adenosine signaling pathway that can suppress immune responses in the tumor microenvironment. By inhibiting CD73, ORIC-533 is designed to support antitumor immune activity in multiple myeloma.
ORIC-533 is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol ORIC. The company is the sponsor of the clinical program evaluating ORIC-533 in relapsed or refractory multiple myeloma.
ORIC-533 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 study evaluating ORIC-533 in relapsed or refractory multiple myeloma has been completed.
ORIC-533 has been evaluated in one Phase 1 clinical trial, NCT05227144, titled Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma. The trial enrolled 31 participants across sites in the United States and Canada and is listed as completed.
The Phase 1 trial NCT05227144 was a controlled study of ORIC-533 in adults 18 years and older with relapsed or refractory multiple myeloma. It was not randomized and not double blinded, enrolled 31 participants, and included sites in the United States and Canada.